Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 45.90% | -36.81% | -52.30% | -50.80% | -286.31% |
| Total Depreciation and Amortization | -5.42% | -9.83% | -6.43% | 0.00% | 12.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -86.22% | 51.00% | 406.66% | 231.46% | 2,399.43% |
| Change in Net Operating Assets | 89.66% | 2,567.23% | -277.22% | 1,062.14% | -153.27% |
| Cash from Operations | 2.14% | 29.91% | -81.03% | -30.01% | -69.41% |
| Capital Expenditure | 1,861.36% | 100.00% | -- | -2,052.78% | -91.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -825.71% | 558.18% | -11.72% | -5,330.49% | 271.36% |
| Cash from Investing | -822.37% | 559.20% | -11.72% | -5,424.85% | 270.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,427.43% | -99.25% | 556.93% | 206.48% | 707.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 127.44% | 92.14% | -- | -- | -3,137.04% |
| Cash from Financing | 3,337.63% | -99.34% | 808.90% | 1,726.73% | -101.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -249.23% | -39.91% | -384.80% | -534.44% | -230.76% |
